


DDE Labs Spring 2020 Newsletter

CORONAVIRUS

A Message to Our Clients, Colleagues, and Friends



We hope you are keeping safe and healthy and that you and your family have not been adversely impacted by events surrounding the Coronavirus.

While much of the United States is under a lock-down, DDE Labs is committed to supporting our client project work.

Although our lab is closed to the public and most of the staff are working from home, essential personnel in the lab are working to keep to our agreed timelines to the best of our ability during this challenging time. We are taking extra precautions to ensure that staff stays safe by wearing masks and gloves in addition to the standard PPE for laboratory work.

Also, plans to upgrade our facility to GMP (see the update below) will continue although with minimal on-site personnel. During this unprecedented time, we believe converting our process suite to GMP could be an asset to the community as well as our clients for the production of clinical supplies and toxicity test articles.

In addition, we have donated excess gloves, masks, and gowns to one of the local hospitals.

We understand that pharmaceutical research and development will not grind to a halt, and have already been contacted by some to take advantage of our operational laboratory.

We are available to talk about your current and future projects if you have questions during this difficult time. Either email your contact at DDE Labs or contact us for a new project discussion by emailing bd@ddelabs.com.

GMP FACILITY

DDE Labs Announces GMP Capability for Q3 of 2020

DDE Labs has added GMP capabilities to its array of services. This expanded capability will be used primarily to support our clients who require clinical trial materials.

"We are pleased to enhance our capabilities by providing GMP fill finish services to our clients to support them throughout the clinical trial process," said Chris Rhodes, Ph.D, CEO & President.

Simple and complex formulations alike will be able to be turned around quickly without the need for a technology transfer.

"These services, coupled with DDE's 6-year track record of drug product development, will give our clients a complete process that meets their timeline and compliance requirements and protects intellectual property," added Rhodes.

DDE Labs anticipates completing the implementation of GMP fill finish capabilities in Q3 2020. For more information, please visit our GMP page.

[More](#)



STAFF NEWS

Franco Ferrari, Ph.D. Joins DDE Labs Heading-Up GMP Upgrade



Please join us in giving a warm and hearty DDE welcome to Franco Ferrari who is joining us as Scientific Director, GMP Operations and Manufacturing.

He comes from a long history of CMC and quality management positions in pharma and biotech companies. Franco will be leading the effort to implement the GMP Manufacturing and Quality System for the Process Suite in Q3 2020.

He is also a great cook! Welcome onboard Franco!

[More](#)

PARTNERSHIP NEWS

Veru and DDE Publish First Results of Long-Acting GnRH Anagonist

VERU-100 is a novel, proprietary peptide formulation that has been fast-tracked by the FDA for clinical development and was co-developed at DDE Labs.



Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company is publishing results from an animal study for Veru-100 which will enter clinical trials in the near future. This product has several beneficial clinical attributes for addressing the androgen deprivation therapy market for advanced prostate cancer and should be a go to product in the space once approved.

[Download the Poster](#)

EVENTS

LAI 2020 Conference a Huge Success



DDE Labs in co-sponsorship with the Controlled Release Society hosted the 3rd Long-Acting Injectables & Implantables Conference in La Jolla, California on Feb. 6-7, 2020.

The event had over 190 attendees, 21 speakers, 9 industry sponsors and was designed to bring together the long-acting technology community. The meeting also featured a unique expert panel which discussed the importance of bringing long-acting therapeutics to the lower and middle income economies (pictured left).

If you missed it, stay tuned at laiconference.org for updates and more information about next year's meeting, which will again be held in La Jolla on Feb. 4-5, 2021. You can also download select presentations from the 2019 meeting.

[More](#)



[Visit Our Website](#)

[Schedule A Meeting](#)

Find DDE Labs At:



Stay in Touch With DDE Labs

As an increasing number of scientific and pharmaceutical conferences that we attend are cancelled or postponed, you can stay in contact with DDE Labs by emailing bd@ddelabs.com.